Insider Selling: Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Sells 4,000 Shares of Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 4,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $72.68, for a total transaction of $290,720.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jason Douglas Wilson also recently made the following trade(s):

  • On Monday, July 15th, Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $84.64, for a total transaction of $338,560.00.
  • On Monday, June 17th, Jason Douglas Wilson sold 4,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $83.54, for a total transaction of $334,160.00.

RETA traded up $2.75 on Friday, reaching $75.74. The stock had a trading volume of 225,792 shares, compared to its average volume of 227,253. Reata Pharmaceuticals Inc has a 12-month low of $47.50 and a 12-month high of $104.53. The company has a current ratio of 4.24, a quick ratio of 5.19 and a debt-to-equity ratio of 5.23. The business’s 50-day moving average price is $87.49 and its two-hundred day moving average price is $87.15. The company has a market cap of $2.19 billion, a P/E ratio of -26.39 and a beta of 2.31.



Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.02). Reata Pharmaceuticals had a negative net margin of 410.38% and a negative return on equity of 3,282.73%. The firm had revenue of $7.83 million during the quarter, compared to analysts’ expectations of $7.76 million. As a group, analysts predict that Reata Pharmaceuticals Inc will post -4.56 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RETA. Resources Investment Advisors LLC. purchased a new position in Reata Pharmaceuticals in the second quarter valued at $25,000. Meadow Creek Investment Management LLC grew its position in shares of Reata Pharmaceuticals by 71.4% in the second quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock valued at $32,000 after purchasing an additional 140 shares during the period. Glen Harbor Capital Management LLC grew its position in shares of Reata Pharmaceuticals by 71.4% in the second quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock valued at $39,000 after purchasing an additional 170 shares during the period. Optimum Investment Advisors acquired a new stake in shares of Reata Pharmaceuticals in the second quarter valued at about $76,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Reata Pharmaceuticals by 100.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 991 shares of the company’s stock valued at $85,000 after purchasing an additional 496 shares during the period. 54.71% of the stock is owned by institutional investors.

Several research analysts recently issued reports on RETA shares. Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 11th. Citigroup raised their target price on shares of Reata Pharmaceuticals from $190.00 to $194.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, BidaskClub cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $141.50.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Further Reading: Growth and Income Funds

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.